PA
ASND icon

PharVision Advisers’s Ascendis Pharma A/S ASND Stock Holding History

PharVision Advisers’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,122
Closed -$239K – 138
2025
Q4 		$239K Sell
1,122
-48
-4% -$9.91K 0.12% 424
2025
Q3 		$233K Buy
+1,170
New +$218K 0.13% 387

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

PharVision Advisers's ASND Position: Q1 2026 in Review

PharVision Advisers sold out of Ascendis Pharma A/S (ASND) in Q1 2026, closing a stake of 1,122 shares — an estimated $239K sold.

PharVision Advisers first reported a position in ASND in Q3 2025 and held it in 2 quarters. The position peaked at $239K in Q4 2025. 274 funds tracked by Wall St. Rank hold ASND as of Q1 2026.

  • PharVision Advisers reported no remaining Ascendis Pharma A/S position as of Q1 2026 after selling out during the quarter.
  • PharVision Advisers sold 1,122 Ascendis Pharma A/S shares in Q1 2026, an estimated $239K.
  • PharVision Advisers first reported a position in Ascendis Pharma A/S in Q3 2025 and held it in 2 quarters.
  • PharVision Advisers's Ascendis Pharma A/S position peaked at $239K in Q4 2025.
  • 274 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.